Artificial Intelligence (AI) is transforming the pharmaceutical landscape, offering unprecedented opportunities across the medicines lifecycle, from drug discovery and clinical development to manufacturing and post-approval safety monitoring. As AI becomes more deeply embedded in regulatory decision-making and processes that impact patients, the need for robust governance becomes critical.

This report presents a cross-industry perspective on how AI governance can be integrated effectively into medicinal product research and development (R&D) and post authorisation settings, with a focus on ensuring trust, transparency, and regulatory alignment through ongoing dialogue between industry and regulators.

Read the full report here.